Literature DB >> 2190938

Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients.

D M Euhus1, R K Gupta, D L Morton.   

Abstract

Using allogeneic antibody, we previously described a high-molecular-weight glycoprotein in the urine of 68% of melanoma patients. This glycoprotein has been termed urinary-tumor-associated antigen (U-TAA). A murine monoclonal antibody (MAb) specific for U-TAA (ADI-40F4) has been developed. By the use of ADI-40F4, U-TAA was detected in serum samples from 63% (33/52) of stage II and stage III melanoma patients, but from only 5% (1/20) of normal controls. This report describes the physical and immunochemical properties of U-TAA in the serum. The antigen elutes from a DEAE-Sephacel column in association with IgG in the void volume and as free antigen in a second peak. The molecular mass of the free antigen is 590-620 kDa and it sediments in the region of 28-29% sucrose by density gradient ultracentrifugation. Free antigen has an isoelectric point of 6.1. This high molecular weight antigen is composed of smaller subunits linked by reducible bonds. The ADI-40F4 reactive epitope resides on a 90-100 kDa subunit. These results provide evidence that U-TAA which is produced by melanoma cells in vitro is present in the circulation of melanoma patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190938     DOI: 10.1002/ijc.2910450615

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen.

Authors:  K K Hunt; M Shibata; R K Gupta; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 2.  Melanoma vaccines. Current status and future prospects.

Authors:  P Hersey
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

3.  Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.

Authors:  R C Jones; M Kelley; R K Gupta; J A Nizze; R Yee; Z Leopoldo; K Qi; S Stern; D L Morton
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

4.  Noncytolytic inhibition of X4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines.

Authors:  R Geiben-Lynn; M Kursar; N V Brown; E L Kerr; A D Luster; B D Walker
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Association between allo-immunoreactive and xeno-immunoreactive subunits of a glycoprotein tumor-associated antigen.

Authors:  D M Euhus; R K Gupta; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.